Trial · NCT03467425
Adverse events258
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
21 to 40 of 258
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Pleural effusion | Respiratory, thoracic and mediastinal disorders | FF /UMEC/VI: 100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI | 0 | 1,545 | 0 |
| serious | Pleural effusion | Respiratory, thoracic and mediastinal disorders | Non-Ellipta MITT | 4 | 1,547 | 4 |
| serious | Respiratory failure | Respiratory, thoracic and mediastinal disorders | FF /UMEC/VI: 100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI | 3 | 1,545 | 4 |
| serious | Respiratory failure | Respiratory, thoracic and mediastinal disorders | Non-Ellipta MITT | 1 | 1,547 | 1 |
| serious | Breast cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | FF /UMEC/VI: 100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI | 1 | 1,545 | 1 |
| serious | Breast cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Non-Ellipta MITT | 2 | 1,547 | 2 |
| serious | Dyspnoea | Respiratory, thoracic and mediastinal disorders | FF /UMEC/VI: 100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI | 1 | 1,545 | 1 |
| serious | Dyspnoea | Respiratory, thoracic and mediastinal disorders | Non-Ellipta MITT | 2 | 1,547 | 2 |
| serious | Humerus fracture | Injury, poisoning and procedural complications | FF /UMEC/VI: 100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI | 2 | 1,545 | 2 |
| serious | Humerus fracture | Injury, poisoning and procedural complications | Non-Ellipta MITT | 1 | 1,547 | 1 |
| serious | Lung neoplasm malignant | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | FF /UMEC/VI: 100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI | 1 | 1,545 | 1 |
| serious | Lung neoplasm malignant | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Non-Ellipta MITT | 2 | 1,547 | 2 |
| serious | Peripheral arterial occlusive disease | Vascular disorders | FF /UMEC/VI: 100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI | 2 | 1,545 | 2 |
| serious | Peripheral arterial occlusive disease | Vascular disorders | Non-Ellipta MITT | 1 | 1,547 | 1 |
| serious | Peripheral ischaemia | Vascular disorders | FF /UMEC/VI: 100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI | 1 | 1,545 | 1 |
| serious | Peripheral ischaemia | Vascular disorders | Non-Ellipta MITT | 2 | 1,547 | 2 |
| serious | Prostate cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | FF /UMEC/VI: 100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI | 1 | 1,545 | 1 |
| serious | Prostate cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Non-Ellipta MITT | 2 | 1,547 | 2 |
| serious | Pulmonary embolism | Respiratory, thoracic and mediastinal disorders | FF /UMEC/VI: 100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI | 3 | 1,545 | 3 |
| serious | Pulmonary embolism | Respiratory, thoracic and mediastinal disorders | Non-Ellipta MITT | 0 | 1,547 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03467425/events?page=2